Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has acquired Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share.
Subscribe to our email newsletter
Through the acquisition of Sirtris, GlaxoSmithKline (GSK) has significantly enhanced its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process.
Sirtris will become part of GSK’s drug discovery organization, while continuing to operate from laboratories in Cambridge, Massachusetts, as an autonomous drug discovery unit.
Christoph Westphal, CEO and vice chair of Sirtris, and the management team will continue to lead this autonomous unit.